Healing & Recovery

A pentadecapeptide studied extensively in animal models for tendon, ligament, muscle, and gut healing. Human evidence remains limited.

A synthetic version of Thymosin Beta-4 studied in animal models for wound healing, tissue repair, and reduced inflammation.

A naturally occurring copper-binding tripeptide widely used in skincare and studied for wound healing and skin remodeling.

A naturally occurring actin-binding peptide studied for wound healing, cardiac repair, and eye conditions; the parent molecule of TB-500.

An EPO-derived peptide that activates tissue-protective repair signaling without raising red blood cells, studied for nerve pain in sarcoidosis.

A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models.

An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.

A signaling peptide with broad roles in immunity, inflammation, and blood flow, studied intranasally for chronic inflammatory conditions.

An injected Wnt-pathway small molecule for knee osteoarthritis, given once or twice a year, with an NDA submitted to the FDA in January 2026 after multi-year cartilage-preservation data.

The same 15 amino acid sequence as BPC-157 with an arginine salt instead of acetate, created as a compounding workaround; it has no studies of its own and inherits BPC-157's animal-only evidence.

A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation; no study has ever tested the combination, and GHK-Cu makes up most of the vial.

An approved eye drug that, injected into wounds in mice, produced regeneration without scars in a landmark 2021 Science paper; the first human scar trial started in June 2026, and off-label self-use carries days of severe photosensitivity.

The N-terminal four amino acids of thymosin beta-4, a natural anti-fibrotic peptide broken down by ACE (which is why ACE inhibitors raise it); animal and human observational data, sold as capsules unlikely to survive digestion.

A simplified relaxin analog that activates the RXFP1 receptor with a bias toward anti-fibrotic signaling; animal and cell data only.